WACO, Texas—Allergan plc (NYSE: AGN), broke ground Monday on a $200 million expansion of its Waco, Texas facility. The company said the expansion will add 322,000 square feet of manufacturing space to the current facility, nearly doubling its current footprint.

Once completed, the expansion is expected to add approximately 100 full-time jobs, with the potential for the expanded operations adding as many as 250 full-time jobs as the facility reaches full utilization. New positions that will be added include chemists, microbiologists, process engineers and production and maintenance technicians.

Additionally, the facility expansion will upgrade Allergan’s manufacturing capabilities and capacity. The expansion will add a new raw material dispensary, an automated bulk formulation suite and 10 new state-of-the-art production lines as well as warehousing space. Upon completion, the Waco facility will be capable of producing more than 40 different product formulations and will increase its production capacity by more than 50 percent.

The construction, commissioning and validation of the facility expansion and production processes are expected to be completed by 2020. Allergan's Waco facility is the company's flagship manufacturing facility for its leading eyecare products, including Restasis, Lumigan, Combigan, Refresh Plus, Refresh Tears and Latisse.